Levosimendan: Perpetuum mobile?
We read with great interest the well-written review about levosimendan by De Luca et al. 1 Levosimendan is certainly an interesting drug that appears to deliver favourable effects in patients with acute heart failure. Numerous studies have demonstrated the positive inotropic action of levosimendan. In 1998, Lilleberg et al.
2 published in this journal an interesting article, which is quoted very often in articles dealing with levosimendan. These authors reported that levosimendan increases cardiac output and stroke volume in patients after coronary bypass surgery, neither increasing myocardial oxygen consumption nor changing myocardial substrate utilization. This observation has been accepted as a fact and has not been challenged.
Cardiac excitation-contraction coupling (EC coupling) is an energy-consuming process. 3 Changes in cardiac contractile force can be effected at each of three distinct levels: (i) the modulation of intracellular calcium; (ii) the alteration of the contractile protein response to intracellular calcium; and (iii) changes in loading conditions. Of note, regardless at which level of EC coupling levosimendan exerts its action, it will always act at the expense of energy substrate.
Based on these considerations we do believe that a drug which increases myocardial contractility certainly also increases energy consumption, otherwise levosimedan is the driving force of a cardiac 'perpetuum mobile'. Variability in response to clopidogrel: where is the threshold for 'low response'?
Stefan Agewall
We read with great interest the recent trial of Geisler et al. 1 investigating the influence of low response to clopidogrel on the 3-month composite endpoint in 379 patients after coronary stent implantation. The authors identified 'low-responders' to clopidogrel therapy with a single measurement of optical aggregometry and found that these patients had significantly more major cardiovascular (CV) events within 3 months than those with adequate response. Regarding the outcome, the rate of adverse CV events appears to be unexpectedly high, reaching 8.0% with all-cause death, stroke, and myocardial infarction vs. 0-3% in similar studies.
2 This is mainly driven by the particularly high mortality rate (all-cause, 5.2%; cardiac, 3.9%) in 3-month time. As the main difference between low-and adequateresponders was registered as divergence in mortality, this might be of substantial importance. Furthermore, there were significantly more acute coronary syndrome patients among the low-responders (43.1 vs. 81.8%, P , 0.001), that itself, may have resulted in higher mortality of this group. Statins (88.3 vs. 72.7%, P ¼ 0.06) and betablockers (94.4 vs. 81.8%, P ¼ 0.05) were also less frequently administered to these patients. These uncontrolled factors may have biased the statistical analysis. Apart from the above-mentioned facts, the results of the study are in line with recent observations. We have recently presented our data of the link between efficacy of thienopyridine therapy and need for repeat revascularization after coronary stent implantation, 3 while Hochholzer et al.
